Changes of Antimicrobial Resistance Causing Infections Following Transrectal Prostate Biopsy: Analysis of 10-Year Data
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Da Eun Han | - |
dc.contributor.author | Sun Tae Ahn | - |
dc.contributor.author | Jong Wook Kim | - |
dc.contributor.author | Du Geon Moon | - |
dc.contributor.author | Hong Seok Park | - |
dc.contributor.author | Mi Mi Oh | - |
dc.date.accessioned | 2022-11-05T05:42:12Z | - |
dc.date.available | 2022-11-05T05:42:12Z | - |
dc.date.created | 2022-11-04 | - |
dc.date.issued | 2021 | - |
dc.identifier.issn | 2465-8243 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/144773 | - |
dc.description.abstract | Purpose: The production of extended-spectrum -lactamases (ESBLs) has emerged as one of the main causes of antimicrobial resistance. It is well known that infections of ESBL-producing Enterobacteriaceae causes poor clinical outcomes. This study investigated the changes in the antimicrobial resistance patterns in infections following transrectal ultrasound-guided prostate (TR) biopsy over a 10 year period and analyzed whether the clinical course varies in infections caused by the ESBL-producing Enterobacteriaceae. Materials and Methods: We retrospectively analyzed patients who had infections after a TR biopsy at the Korea University Guro Hospital from January 2010 to October 2019. Infection from a TR biopsy was defined as readmission due to a fever of 38 degrees or higher that occurred within one week after the biopsy. Results: Among 1,855 patients who received a TR biopsy, 39 patients (2.10%) had infectious complications. Of 33 culture-positive patients, 29 patients (87.9%) showed quinolone resistance, 10 patients (30.3%) were ESBL-positive and 9 patients had concomitant quinolone resistance and were also ESBL-positive. 75% of ESBL-positive bacterial infections occurred after 2016 indicating increasing incidence in recent days. The only significant difference in the clinical course between the ESBL-negative and the positive group was the lower systolic blood pressure of the ESBL-positive group during hospitalization (p-value=0.018). Conclusions: Infections due to the ESBL-producing Enterobacteriaceae showed a tendency to increase among TR biopsy patients since 2016. Although the clinical course of the ESBL-positive infection did not show significant differences to ESBL-negative infection, further analysis is needed because of the small number of patients. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | 대한요로생식기감염학회 | - |
dc.title | Changes of Antimicrobial Resistance Causing Infections Following Transrectal Prostate Biopsy: Analysis of 10-Year Data | - |
dc.title.alternative | Changes of Antimicrobial Resistance Causing Infections Following Transrectal Prostate Biopsy: Analysis of 10-Year Data | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Jong Wook Kim | - |
dc.identifier.doi | 10.14777/uti.2021.16.3.55 | - |
dc.identifier.bibliographicCitation | Urogenital Tract Infection, v.16, no.3, pp.55 - 60 | - |
dc.relation.isPartOf | Urogenital Tract Infection | - |
dc.citation.title | Urogenital Tract Infection | - |
dc.citation.volume | 16 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 55 | - |
dc.citation.endPage | 60 | - |
dc.type.rims | ART | - |
dc.identifier.kciid | ART002800813 | - |
dc.description.journalClass | 2 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Prostate | - |
dc.subject.keywordAuthor | Biopsy | - |
dc.subject.keywordAuthor | Transrectal | - |
dc.subject.keywordAuthor | Infections | - |
dc.subject.keywordAuthor | Beta-lactam resistance | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.